ArticleKidney international2016
APOL1 renal-risk genotypes associate with longer hemodialysis survival in prevalent nondiabetic African American patients with end-stage renal disease.
Article in Kidney international, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 28 citations in OpenAlex.
- Trial
- Blood pressure andClinical kidney journal · 2026Article
- At Europe's migration crossroads: dialysis outcomes and transplant access in patients immigrating to Belgium.Clinical kidney journal · 2026Article
- Integrated bioinformatics and machine learning reveal key genes and immune mechanisms associated with uremia.Scientific reports · 2025Article
- APOL1 Risk Variants Associated with Serum Albumin in a Population-Based Cohort Study.American journal of nephrology · 2022Article
- Article
- Kidney Disease-AssociatedJournal of the American Society of Nephrology : JASN · 2020Article
- APOL1 Nephropathy Risk Alleles and Mortality in African American Adults: A Cohort Study.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2020Article
- Risk of Cardiovascular Disease and Mortality in Young Adults With End-stage Renal Disease: An Analysis of the US Renal Data System.JAMA cardiology · 2019Article
- Biomarkers in Solid Organ Transplantation.Clinics in laboratory medicine · 2019Review
- Article
- Genetics, Genomics, and Precision Medicine in End-Stage Kidney Disease.Seminars in nephrology · 2018Review
- Article
- Article
- APOL1 nephropathy risk variants do not associate with subclinical atherosclerosis or left ventricular mass in middle-aged black adults.Kidney international · 2018Article
- APOL1 Gene Kidney Risk Variants and Cardiovascular Disease: Getting to the Heart of the Matter.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2017Review
- Article
- Strict blood pressure control associates with decreased mortality risk by APOL1 genotype.Kidney international · 2017Article
- APOL1 risk variants and kidney disease: what we know so far.Jornal brasileiro de nefrologiaReview
Corrections and comments
- Commented on by
Authors and funding
14 authors at 4 institutions in 1 country.
Funding
Abstract
Relative to European Americans, evidence supports that African Americans with end-stage renal disease (ESRD) survive longer on dialysis. Renal-risk variants in the apolipoprotein L1 gene (APOL1), associated with nondiabetic nephropathy and less subclinical atherosclerosis, may contribute to dialysis outcomes. Here, APOL1 renal-risk variants were assessed for association with dialytic survival in 450 diabetic and 275 nondiabetic African American hemodialysis patients from Wake Forest and Emory School of Medicine outpatient facilities. Outcomes were provided by the ESRD Network 6-Southeastern Kidney Council Standardized Information Management System. Dates of death, receipt of a kidney transplant, and loss to follow-up were recorded. Outcomes were censored at the date of transplantation or through 1 July 2015. Multivariable Cox proportional hazards models were computed separately in patients with nondiabetic and diabetic ESRD, adjusting for the covariates age, gender, comorbidities, ancestry, and presence of an arteriovenous fistula or graft at dialysis initiation. In nondiabetic ESRD, patients with 2 (vs. 0/1) APOL1 renal-risk variants had significantly longer dialysis survival (hazard ratio 0.57), a pattern not observed in patients with diabetes-associated ESRD (hazard ratio 1.29). Thus, 2 APOL1 renal-risk variants are associated with longer dialysis survival in African Americans without diabetes, potentially relating to presence of renal-limited disease or less atherosclerosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.